KeyCorp Research Analysts Lift Earnings Estimates for INSP

Inspire Medical Systems, Inc. (NYSE:INSP) – Stock analysts at KeyCorp lifted their FY2025 earnings per share estimates for Inspire Medical Systems in a research note issued to investors on Sunday, January 25th. KeyCorp analyst B. Fishbin now expects that the company will earn $1.63 per share for the year, up from their prior forecast of $1.57. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share. KeyCorp also issued estimates for Inspire Medical Systems’ Q4 2025 earnings at $0.70 EPS and FY2026 earnings at $1.81 EPS.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.53. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The company had revenue of $224.50 million during the quarter, compared to analysts’ expectations of $220.39 million. During the same period last year, the business earned $0.60 earnings per share. Inspire Medical Systems’s quarterly revenue was up 10.5% on a year-over-year basis.

Several other analysts have also commented on the stock. Wells Fargo & Company dropped their price target on shares of Inspire Medical Systems from $160.00 to $145.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 14th. UBS Group set a $96.00 target price on Inspire Medical Systems in a research report on Thursday, January 22nd. Royal Bank Of Canada lowered Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $175.00 to $90.00 in a research note on Tuesday. Morgan Stanley reiterated an “equal weight” rating and set a $130.00 price target (up previously from $105.00) on shares of Inspire Medical Systems in a research report on Tuesday, December 2nd. Finally, Piper Sandler raised their price objective on Inspire Medical Systems from $135.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Inspire Medical Systems presently has an average rating of “Hold” and an average price target of $133.47.

Inspire Medical Systems Price Performance

Shares of NYSE INSP opened at $82.01 on Wednesday. The firm’s 50 day simple moving average is $105.93 and its 200-day simple moving average is $95.77. Inspire Medical Systems has a 12 month low of $70.77 and a 12 month high of $203.12. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of 55.79, a PEG ratio of 8.25 and a beta of 0.72.

Institutional Trading of Inspire Medical Systems

A number of institutional investors have recently made changes to their positions in INSP. M&T Bank Corp acquired a new position in Inspire Medical Systems in the 4th quarter valued at $85,871,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Inspire Medical Systems by 990.1% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 38,404 shares of the company’s stock worth $3,542,000 after purchasing an additional 34,881 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Inspire Medical Systems by 5.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,265 shares of the company’s stock worth $855,000 after buying an additional 507 shares in the last quarter. Hedges Asset Management LLC raised its position in shares of Inspire Medical Systems by 11.4% in the fourth quarter. Hedges Asset Management LLC now owns 3,900 shares of the company’s stock valued at $360,000 after buying an additional 400 shares during the last quarter. Finally, Bayforest Capital Ltd purchased a new position in shares of Inspire Medical Systems in the fourth quarter worth about $222,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares in the company, valued at approximately $3,320,344.08. The trade was a 7.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.30% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.